OBJECTIVE: (a) To evaluate body fat in men with prolactinoma and healthy controls, using whole body dual energy x-ray absorptiometry (DXA), and (b) to correlate DXA results with anthropometry and clinical aspects of male prolactinomas. MATERIAL AND METHODS: A cross-sectional study was performed in two University referral centers. Eleven newly-diagnosed men with prolactinoma and 9 with normal PRL levels due to dopamine agonist treatment were submitted to DXA and blood analysis (PRL, testosterone, dihydrotestosterone, estradiol, and SHBG) by the time of their clinical evaluation. They were compared with 14 control men of similar age and body mass index distribution. RESULTS: Newly-diagnosed men with prolactinoma had higher fat percentage in the arms and the total body, when compared with patients treated with dopamine agonists and controls. The former group also presented higher fat percentage in the legs than the controls. Truncal fat percentage of the newly-diagnosed patients was lower than the dopamine agonist treated group. The 3 groups had similar android and gynoid fat contents. Fat percentage of the 6 sites correlated with PRL, testosterone, and dihydrotestosterone levels. CONCLUSION: Newly-diagnosed men with prolactinomas had higher body fat content. Body fat was linked to disease control, especially to the PRL and androgen levels. Consequently, adequate control of hyperprolactinemia should be pursued in order to reduce the risk of obesity and its metabolic complications in men with prolactinoma.
OBJECTIVE: (a) To evaluate body fat in men with prolactinoma and healthy controls, using whole body dual energy x-ray absorptiometry (DXA), and (b) to correlate DXA results with anthropometry and clinical aspects of male prolactinomas. MATERIAL AND METHODS: A cross-sectional study was performed in two University referral centers. Eleven newly-diagnosed men with prolactinoma and 9 with normal PRL levels due to dopamine agonist treatment were submitted to DXA and blood analysis (PRL, testosterone, dihydrotestosterone, estradiol, and SHBG) by the time of their clinical evaluation. They were compared with 14 control men of similar age and body mass index distribution. RESULTS: Newly-diagnosed men with prolactinoma had higher fat percentage in the arms and the total body, when compared with patients treated with dopamine agonists and controls. The former group also presented higher fat percentage in the legs than the controls. Truncal fat percentage of the newly-diagnosed patients was lower than the dopamine agonist treated group. The 3 groups had similar android and gynoid fat contents. Fat percentage of the 6 sites correlated with PRL, testosterone, and dihydrotestosterone levels. CONCLUSION: Newly-diagnosed men with prolactinomas had higher body fat content. Body fat was linked to disease control, especially to the PRL and androgen levels. Consequently, adequate control of hyperprolactinemia should be pursued in order to reduce the risk of obesity and its metabolic complications in men with prolactinoma.
Authors: J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: A Chrisoulidou; S A Beshyah; O Rutherford; T J Spinks; J Mayet; P Kyd; V Anyaoku; A Haida; B Ariff; M Murphy; E Thomas; S Robinson; R Foale; D G Johnston Journal: J Clin Endocrinol Metab Date: 2000-10 Impact factor: 5.958
Authors: Rosa Pirchio; Renata S Auriemma; Domenico Solari; Mauro Arnesi; Claudia Pivonello; Mariarosaria Negri; Cristina de Angelis; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello Journal: Front Endocrinol (Lausanne) Date: 2021-11-30 Impact factor: 5.555
Authors: Verena Schwetz; Rosaria Librizzi; Christian Trummer; Georg Theiler; Claudia Stiegler; Thomas R Pieber; Barbara Obermayer-Pietsch; Stefan Pilz Journal: Metab Brain Dis Date: 2016-08-15 Impact factor: 3.584